Home › Learn › What Is Nicotinamide Riboside? NR, NAD+, and What Human Trials Measured

What Is Nicotinamide Riboside? NR, NAD+, and What Human Trials Measured

Published 2026-09-16 · Last reviewed 2026-09-16 · By Andy Palenzuela, Founder

Nicotinamide riboside (NR) is the NAD+ precursor with the most published human pharmacokinetic data, and also the one most often explained badly — either as a miracle molecule or as "just vitamin B3." Neither is accurate. This article explains what NR is, how the body converts it to NAD+, what the three most-cited human trials actually measured (and did not), what doses they used, and how to read an NR label. It is written by the founder of Age Revive, who spent 14+ years inside regulated nutrition supply chains before formulating CELLUNAD+ around 500 mg of NR.

Key facts

  • Nicotinamide riboside (NR): is a form of vitamin B3, found in trace amounts in milk. The body converts it to NAD+ in two enzymatic steps: NR → NMN → NAD+.
  • NAD+: (nicotinamide adenine dinucleotide) is a coenzyme in every living cell. It shuttles electrons in the reactions that turn food into usable energy and is consumed by enzymes involved in cellular maintenance.
  • Human trials: single doses of 100, 300, and 1,000 mg raised blood NAD+ metabolites dose-dependently (Trammell 2016); 1,000 mg/day for 6 weeks was well tolerated in adults 55–79 (Martens 2018); 100, 300, and 1,000 mg/day for 8 weeks was well tolerated in healthy overweight adults, with dose-dependent increases in blood NAD+ (Conze 2019).
  • Doses studied: 100–1,000 mg/day. CELLUNAD+ provides 500 mg/day, alongside methylation co-factors, apigenin, and R-lipoic acid.
  • NR does not cause flushing: That is a property of nicotinic acid (niacin), a different B3 form.
  • None of these trials tested a finished supplement: They tested NR as an ingredient. CELLUNAD+ was not in any of them.

What nicotinamide riboside is

Nicotinamide riboside is a pyridine nucleoside — a nicotinamide ring attached to a ribose sugar. Chemically it belongs to the vitamin B3 family, alongside nicotinic acid (niacin) and nicotinamide (niacinamide). It occurs naturally in small amounts in milk and yeast.

What distinguishes NR from the other B3 forms is the route it takes to NAD+. Niacin and nicotinamide enter through pathways that involve more steps or carry side effects at high doses (niacin's flushing is the well-known example). NR is phosphorylated directly by enzymes called nicotinamide riboside kinases (NRK1 and NRK2) to nicotinamide mononucleotide (NMN), and NMN is converted to NAD+ by NMNAT enzymes. Two steps, no flushing, no nicotinamide accumulation at the front end.

The supplement form is nicotinamide riboside chloride — the salt used in all three human trials cited below.

What NAD+ does, in plain English

NAD+ is not an "energy molecule" in the sense a marketer means it. It is a coenzyme — a helper that enzymes need to do their jobs — and it has two broad roles:

  1. Redox. NAD+ accepts electrons (becoming NADH) and hands them off inside mitochondria, which is how the energy in food becomes the energy cells run on. This is the reason "cellular energy metabolism" appears on NAD+ labels — it is a description of the chemistry, not a promise of how you will feel.
  2. Substrate. Several enzyme families consume NAD+ outright: sirtuins (involved in cellular maintenance and gene regulation), PARPs (involved in DNA repair processes), and CD38 (an enzyme whose activity has been reported to rise with age). Every time one of these enzymes uses NAD+, it releases nicotinamide, which the body either recycles or clears.

Tissue NAD+ levels have been reported to decline with age in a number of studies. That observation is the entire premise of the precursor category: supply more of the starting material and support NAD+ metabolism as consumption continues.

How NR becomes NAD+

The pathway in one line: NR → NMN → NAD+.

  • NR crosses into the cell and is phosphorylated by NRK1/NRK2 into NMN.
  • NMN is adenylated by NMNAT into NAD+.

Trammell 2016 also found something the field did not expect: after oral NR, blood levels of nicotinic acid adenine dinucleotide (NAAD) rose sharply, even though NAAD was not thought to sit on NR's route to NAD+. The authors proposed NAAD as a sensitive biomarker that NAD+ repletion is occurring. It has been used that way in NR research since.

One consequence of the back half of the pathway matters for formulation. When NAD+ is consumed, the nicotinamide released is partly cleared by an enzyme (NNMT) that spends a methyl group. That is why methylation co-factors appear in a complete NR formula — the reasoning is laid out in Should You Take TMG With NR?.

What the three human trials measured

Trammell 2016 — bioavailability and dose response

The first human pharmacokinetic study of NR. In a pilot, one healthy individual took a single 1,000 mg dose and blood NAD+ rose substantially over the following hours. In the controlled portion, twelve healthy adults took single doses of 100, 300, or 1,000 mg in a crossover design. Blood NAD+ metabolites — including NAD+, its methylated clearance products, and NAAD — rose in a dose-dependent way. No serious adverse events were reported.

What it established: oral NR is bioavailable in humans, and the response scales with dose across 100–1,000 mg.

What it did not: anything about long-term use, or any functional outcome.

Martens 2018 — six weeks at 1,000 mg/day

A randomized, double-blind, placebo-controlled crossover in 24 healthy middle-aged and older adults (ages 55–79). Participants took 500 mg of NR twice daily — 1,000 mg/day — for six weeks, and placebo for six weeks. NR was well tolerated, and NAD+ levels in blood cells were higher during the NR phase than the placebo phase.

What it established: chronic NR at 1,000 mg/day for six weeks is well tolerated in this population and raises blood-cell NAD+.

What it did not: cognitive, energy, or performance outcomes, and nothing at 500 mg/day, which was not a study arm.

Conze 2019 — eight weeks at three doses

A randomized, double-blind, placebo-controlled trial in healthy overweight adults. Participants took 100, 300, or 1,000 mg of NR chloride daily, or placebo, for eight weeks. Whole-blood NAD+ increased dose-dependently and the increases were sustained through the study. NR was well tolerated at all doses, with no clinically relevant differences in adverse events versus placebo.

What it established: eight weeks of daily NR across 100–1,000 mg is well tolerated, and blood NAD+ tracks the dose.

What it did not: weight or metabolic outcomes (not the endpoints), and nothing about any finished product.

What doses did the trials use — and where does 500 mg sit?

TrialDoseDurationPopulationPrimary finding
Trammell 2016100 / 300 / 1,000 mg, single dose1 day (crossover)12 healthy adultsDose-dependent rise in blood NAD+ metabolome
Martens 20181,000 mg/day (500 mg × 2)6 weeks24 adults, 55–79Well tolerated; higher blood-cell NAD+ vs placebo
Conze 2019100 / 300 / 1,000 mg/day8 weeksHealthy overweight adultsWell tolerated; dose-dependent, sustained rise in whole-blood NAD+

Across the published human work, NR has been studied from 100 mg to 1,000 mg per day. The lowest daily dose that produced a clear NAD+ response in Conze 2019 was 300 mg; 1,000 mg produced the largest. There is no trial that identifies an optimal dose, and no trial of 500 mg/day as a standalone arm.

CELLUNAD+ provides 500 mg of NR per daily serving (2 capsules). That is a formulation decision informed by this research: above the 300 mg floor that produced a clear response, below the 1,000 mg used in the longest-running trials, and paired with the co-factors a single-ingredient trial does not address. It is a dose informed by published human research. It is not "clinically proven" — the finished formula has not been in a trial, and we do not say otherwise.

Is nicotinamide riboside safe?

The human trials above are the honest answer. NR chloride at up to 1,000 mg/day was well tolerated over six to eight weeks in healthy adults, including adults in their 60s and 70s, with no clinically relevant differences in adverse events from placebo. NR does not produce the flushing associated with niacin.

Two limits on that answer. First, the trials ran for weeks, not years; long-term data at supplement doses is still accumulating. Second, "well tolerated in healthy adults" is a study population, not a clearance for everyone. If you are pregnant, breastfeeding, managing a condition, or taking medication, that is a conversation with your clinician before starting any supplement.

NR vs the other B3 forms — a short version

  • Niacin (nicotinic acid) raises NAD+ through a separate pathway and causes flushing at higher doses.
  • Nicotinamide (niacinamide) is the form released when NAD+ is consumed; at high doses it can accumulate and is cleared through the methyl-consuming NNMT route.
  • NMN sits one step after NR on the same pathway. It has a growing research base and is a lawful dietary ingredient. The full comparison, including why CELLUNAD+ uses NR rather than NMN, is in NMN vs NR: Two NAD+ Precursors, Compared.

What the research does not show

  • NR has not been shown to "boost your energy." The trials measured blood NAD+ metabolites and tolerability. "Supports NAD+ metabolism" and "supports cellular energy metabolism" describe the chemistry; they are not outcome promises.
  • NR has not been shown to slow, stop, or reverse aging in humans. The age-related decline in NAD+ is an observation; supplementing a precursor is a way to support NAD+ metabolism, not a treatment for aging.
  • No trial has tested CELLUNAD+. The studies tested NR chloride as a single ingredient. Our formula's co-factors were not part of those protocols.
  • No percentage increase applies to you. Trial averages are trial averages. A supplement label that promises "raises NAD+ by X%" is quoting a study population as if it were a guarantee.

How to read an NR label

  1. The form. "Nicotinamide riboside chloride" is what the human trials used. "NAD+ precursor blend" without a named form tells you nothing.
  2. The dose per serving. 100–1,000 mg/day is the studied range. Below 250 mg is decoration.
  3. What comes with it. NAD+ turnover creates methylation demand and is subject to CD38 consumption. A complete formula addresses both; a single-ingredient bottle addresses neither.
  4. Whether it is stimulant-free. Some "NAD+ energy" products add caffeine. That is a spike wearing a foundation's label.
  5. A published lot certificate, with a lab name and tested values.

CELLUNAD+ pairs its 500 mg of NR with TMG, 5-MTHF, methylcobalamin, and P-5-P for methylation balance, 100 mg of apigenin for CD38 pathway interest, 200 mg of R-lipoic acid for mitochondrial cofactor support, and 5 mg of BioPerine for absorption support. Non-stimulant. Every dose on the label.

Frequently asked questions

What is nicotinamide riboside used for? NR is taken as an NAD+ precursor — to support NAD+ metabolism and the cellular energy chemistry NAD+ is involved in. Human trials have measured its bioavailability, its effect on blood NAD+ metabolites, and its tolerability over 6–8 weeks.

How much nicotinamide riboside should I take? Published human trials used 100 to 1,000 mg per day. Conze 2019 saw a clear NAD+ response from 300 mg/day; Martens 2018 used 1,000 mg/day. CELLUNAD+ provides 500 mg per daily serving. Any dose decision belongs with your clinician, especially alongside medication.

Is nicotinamide riboside the same as niacin? No. Both are forms of vitamin B3, but they take different routes to NAD+. Niacin causes flushing at higher doses; NR does not. NR is converted directly to NMN and then NAD+.

Does nicotinamide riboside have side effects? In the three human trials cited, NR chloride at up to 1,000 mg/day for 6–8 weeks was well tolerated, with no clinically relevant differences in adverse events versus placebo. Long-term data is still accumulating.

Sources

  1. Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. 2016;7:12948. doi:10.1038/ncomms12948. PMID 27721479.
  2. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286. doi:10.1038/s41467-018-03421-7. PMID 29599478.
  3. Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports. 2019;9:9772. doi:10.1038/s41598-019-46120-z. PMID 31278280.

Related reading

  • NMN vs NR: Two NAD+ Precursors, Compared — NMN and NR sit one step apart in the same NAD+ pathway. What the human NR studies measured, what they did not, and why CELLUNAD+ uses NR.
  • Should You Take TMG With NR? Methylation and NAD+ Precursors, Explained — Where NR and methylation intersect, what is established biochemistry versus hypothesis, and why TMG alone is only part of the co-factor picture.
  • How to Choose an NAD+ Supplement: The Seven-Check Label Test — Most premium NAD+ brands now print every dose on the label, but transparency alone does not separate a good formula from a lazy one.
  • Apigenin and CD38: What the Research Actually Shows About NAD+ Consumption — Nearly every NAD+ formula is built as a supply problem: add precursor, expect more NAD+.

CELLUNAD+ product page · Science · FAQ · All Learn articles

About the author

Andy Palenzuela is the founder of Age Revive and has 14+ years of experience in regulated nutrition supply chains, including manufacturing oversight, ingredient sourcing, and quality assurance for consumer health products. Age Revive formulas are developed based on published peer-reviewed research and manufactured at cGMP-certified facilities. LinkedIn

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information in this article is for educational purposes only and is not intended as medical advice. Consult your healthcare provider before starting any supplement regimen.